Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 478

1.

Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant.

DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL.

N Engl J Med. 2019 Oct 30. doi: 10.1056/NEJMoa1910437. [Epub ahead of print]

PMID:
31665575
2.

Healthcare Utilization and End of Life Care Outcomes for Patients with Decompensated Cirrhosis based on Transplant Candidacy: End of Life Care for Patients with Cirrhosis.

Ufere NN, Halford JL, Caldwell J, Jang MY, Bhatt S, Donlan J, Ho J, Jackson V, Chung RT, El-Jawahri A.

J Pain Symptom Manage. 2019 Oct 23. pii: S0885-3924(19)30607-4. doi: 10.1016/j.jpainsymman.2019.10.016. [Epub ahead of print]

PMID:
31655192
3.

High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia.

Chihota BV, Wandeler G, Chilengi R, Mulenga L, Chung RT, Bhattacharya D, Egger M, Vinikoor MJ.

J Infect Dis. 2019 Oct 15. pii: jiz450. doi: 10.1093/infdis/jiz450. [Epub ahead of print]

PMID:
31613956
4.

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK.

Lancet HIV. 2019 Oct 11. pii: S2352-3018(19)30338-8. doi: 10.1016/S2352-3018(19)30338-8. [Epub ahead of print]

PMID:
31611038
5.

No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis.

Rutledge SM, Zheng H, Li DK, Chung RT.

Hepatoma Res. 2019;5. pii: 31. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.

6.

Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical Practice.

Bajaj JS, Bloom PP, Chung RT, Hassanein TI, Padilla-Martinez M, Kayali Z, Rockey DC, Sasso R, Muthukumar AR, Lee WM, Denney WS, Gavis EA, Anderson C, Blankstein L, Brennan AM, Puurunen MK, Lawitz E.

Am J Gastroenterol. 2019 Aug 21. doi: 10.14309/ajg.0000000000000384. [Epub ahead of print]

PMID:
31449156
7.

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.

Simon TG, Duberg AS, Aleman S, Hagstrom H, Nguyen LH, Khalili H, Chung RT, Ludvigsson JF.

Ann Intern Med. 2019 Sep 3;171(5):318-327. doi: 10.7326/M18-2753. Epub 2019 Aug 20.

PMID:
31426090
8.

Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes.

Bloom PP, Mojtahed A, Bethea ED, Knooihuizen SA, Choi J, Dienstag JL, Chung RT, Hur C.

Dig Dis Sci. 2019 Jul 30. doi: 10.1007/s10620-019-05721-4. [Epub ahead of print]

PMID:
31363954
9.

Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study.

Bethea ED, Gaj K, Gustafson JL, Axtell A, Lebeis T, Schoenike M, Turvey K, Coglianese E, Thomas S, Newton-Cheh C, Ibrahim N, Carlson W, Ho JE, Shah R, Nayor M, Gift T, Shao S, Dugal A, Markmann J, Elias N, Yeh H, Andersson K, Pratt D, Bhan I, Safa K, Fishman J, Kotton C, Myoung P, Villavicencio MA, D'Alessandro D, Chung RT, Lewis GD.

Lancet Gastroenterol Hepatol. 2019 Oct;4(10):771-780. doi: 10.1016/S2468-1253(19)30240-7. Epub 2019 Jul 26.

PMID:
31353243
10.

Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease.

Sise ME, Chute DF, Oppong Y, Davis MI, Long JD, Silva ST, Rusibamayila N, Jean-Francois D, Raji S, Zhao S, Thadhani R, Chung RT.

Kidney Int. 2019 May 15. pii: S0085-2538(19)30508-3. doi: 10.1016/j.kint.2019.04.030. [Epub ahead of print]

PMID:
31337501
11.

Outcomes of Palliative Care Consultations for Hospitalized Patients With Liver Disease.

Ufere NN, O'Riordan DL, Bischoff KE, Marks AK, Eneanya N, Chung RT, Jackson V, Pantilat SZ, El-Jawahri A.

J Pain Symptom Manage. 2019 Nov;58(5):766-773. doi: 10.1016/j.jpainsymman.2019.07.011. Epub 2019 Jul 19.

PMID:
31326503
12.

Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.

Sterling RK, King WC, Wahed AS, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Hepatology. 2019 Jun 20. doi: 10.1002/hep.30825. [Epub ahead of print]

PMID:
31220357
13.

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.

Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT; Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team .

Clin Infect Dis. 2019 Mar 28. pii: ciy913. doi: 10.1093/cid/ciy913. [Epub ahead of print]

PMID:
31220220
14.

Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals.

Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer A, El-Osta A, Yaari G, Stemmer SM, Yu ML, Haviv I, Gal-Tanamy M.

PLoS Genet. 2019 Jun 19;15(6):e1008181. doi: 10.1371/journal.pgen.1008181. eCollection 2019 Jun.

15.

Editorial: mind the gaps - an important first step towards improving hepatic encephalopathy care.

Bloom PP, Chung RT.

Aliment Pharmacol Ther. 2019 Jun;49(12):1534-1535. doi: 10.1111/apt.15290. No abstract available.

PMID:
31134647
16.

Evaluation of model performance to predict survival after transjugular intrahepatic portosystemic shunt placement.

Allegretti AS, Frenk NE, Li DK, Seethapathy H, Vela Parada XF, Long J, Endres P, Pratt DS, Chung RT, Ganguli S, Irani Z, Yamada K.

PLoS One. 2019 May 23;14(5):e0217442. doi: 10.1371/journal.pone.0217442. eCollection 2019.

17.

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT.

Curr Opin Organ Transplant. 2019 Jun;24(3):351-357. doi: 10.1097/MOT.0000000000000651.

PMID:
31090648
18.

Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.

Simon TG, Henson J, Osganian S, Masia R, Chan AT, Chung RT, Corey KE.

Clin Gastroenterol Hepatol. 2019 May 9. pii: S1542-3565(19)30493-8. doi: 10.1016/j.cgh.2019.04.061. [Epub ahead of print]

PMID:
31077838
19.

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT.

Curr Opin Organ Transplant. 2019 Apr 16. doi: 10.1097/MOT.0000000000000651. [Epub ahead of print]

PMID:
31008739
20.

Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation.

Sise ME, Wojciechowski D, Chute DF, Gustafson J, Chung RT, Williams WW, Elias N.

Artif Organs. 2019 Sep;43(9):913-920. doi: 10.1111/aor.13473. Epub 2019 May 29.

PMID:
31001828
21.

Microrna-130a Downregulates HCV Replication through an atg5-Dependent Autophagy Pathway.

Duan X, Liu X, Li W, Holmes JA, Kruger AJ, Yang C, Li Y, Xu M, Ye H, Li S, Liao X, Sheng Q, Chen D, Shao T, Cheng Z, Kaj B, Schaefer EA, Li S, Chen L, Lin W, Chung RT.

Cells. 2019 Apr 10;8(4). pii: E338. doi: 10.3390/cells8040338.

22.

Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey Study.

Ufere NN, Donlan J, Waldman L, Patel A, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer J, Temel J, Chung RT, El-Jawahri A.

Liver Transpl. 2019 Jun;25(6):859-869. doi: 10.1002/lt.25469. Epub 2019 May 3.

PMID:
30963669
23.

Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver Disease.

Ufere NN, Donlan J, Waldman L, Dienstag JL, Friedman LS, Corey KE, Hashemi N, Carolan P, Mullen AC, Thiim M, Bhan I, Nipp R, Greer JA, Temel JS, Chung RT, El-Jawahri A.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2592-2599. doi: 10.1016/j.cgh.2019.03.022. Epub 2019 Mar 15.

PMID:
30885884
24.

Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.

Corey KE, Wilson LA, Altinbas A, Yates KP, Kleiner DE, Chung RT, Krauss RM, Chalasani N; NASH Clinical Research Network.

Aliment Pharmacol Ther. 2019 May;49(9):1205-1213. doi: 10.1111/apt.15216. Epub 2019 Mar 10.

PMID:
30854694
25.

Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure.

Ajmera V, Huang H, Dao D, Feld JJ, Lau DT, Patel K, Rule JA, Daly M, Lee WM, Chung RT.

Cell Mol Gastroenterol Hepatol. 2019;7(2):477-479.e4. doi: 10.1016/j.jcmgh.2018.09.018. Epub 2018 Oct 17. No abstract available.

26.

Outcomes of in-hospital cardiopulmonary resuscitation for patients with end-stage liver disease.

Ufere NN, Brahmania M, Sey M, Teriaky A, El-Jawahri A, Walley KR, Celi LA, Chung RT, Rush B.

Liver Int. 2019 Jul;39(7):1256-1262. doi: 10.1111/liv.14079. Epub 2019 Mar 26.

PMID:
30809903
27.

Direct-acting antiviral treatment for hepatitis C.

Holmes JA, Rutledge SM, Chung RT.

Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11. No abstract available.

PMID:
30765125
28.

The immunity-related GTPase M rs13361189 variant does not increase the risk for prevalent or incident steatosis; results from the Framingham Heart Study.

Simon TG, Deng X, Liu CT, Chung RT, Long MT.

Liver Int. 2019 Jun;39(6):1022-1026. doi: 10.1111/liv.14039. Epub 2019 Feb 17.

PMID:
30597691
29.

Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.

Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latanich R, Wojcik GL, Taub MA, Valencia A, Thomas DL, Duggal P.

Gastroenterology. 2019 Apr;156(5):1496-1507.e7. doi: 10.1053/j.gastro.2018.12.014. Epub 2018 Dec 26.

PMID:
30593799
30.

Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.

Li DK, Chung RT.

Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1. Review.

PMID:
30593615
31.

Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection.

Hoogeveen RC, Robidoux MP, Schwarz T, Heydmann L, Cheney JA, Kvistad D, Aneja J, Melgaço JG, Fernandes CA, Chung RT, Boonstra A, Kim AY, Baumert TF, Timm J, Lewis-Ximenez LL, Tonnerre P, Lauer GM.

Gut. 2019 May;68(5):893-904. doi: 10.1136/gutjnl-2018-316644. Epub 2018 Dec 22.

PMID:
30580250
32.

Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago.

Couri T, Cotter TG, Chen D, Hammes M, Reddy B, Josephson M, Yeh H, Chung RT, Paul S.

Am J Nephrol. 2019;49(1):32-40. doi: 10.1159/000495263. Epub 2018 Dec 14.

PMID:
30554209
33.

Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.

Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network.

Hepatology. 2019 Jun;69(6):2338-2348. doi: 10.1002/hep.30417. Epub 2019 Mar 14.

PMID:
30549279
34.

Antiviral activity of bone morphogenetic proteins and activins.

Eddowes LA, Al-Hourani K, Ramamurthy N, Frankish J, Baddock HT, Sandor C, Ryan JD, Fusco DN, Arezes J, Giannoulatou E, Boninsegna S, Chevaliez S, Owens BMJ, Sun CC, Fabris P, Giordani MT, Martines D, Vukicevic S, Crowe J, Lin HY, Rehwinkel J, McHugh PJ, Binder M, Babitt JL, Chung RT, Lawless MW, Armitage AE, Webber C, Klenerman P, Drakesmith H.

Nat Microbiol. 2019 Feb;4(2):339-351. doi: 10.1038/s41564-018-0301-9. Epub 2018 Dec 3.

35.

Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.

Holmes JA, Carlton-Smith C, Kim AY, Dumas EO, Brown J, Gustafson JL, Lauer GM, Silva ST, Robidoux M, Kvistad D, Alatrakchi N, Tonnerre P, Cohen DE, Zhang H, Shulman NS, Chung RT.

J Viral Hepat. 2019 Mar;26(3):362-372. doi: 10.1111/jvh.13041. Epub 2019 Jan 3.

PMID:
30450781
36.

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.

Sterling RK, Wahed AS, King WC, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Am J Gastroenterol. 2019 May;114(5):746-757. doi: 10.1038/s41395-018-0409-9.

PMID:
30410040
37.

Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.

Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, Bocobo GA, Tumelty KE, Faugno AJ, Troncone L, McNeil ME, Huang X, Coser KR, Lai CSC, Upton PD, Goumans MJ, Zamanian RT, Elliott CG, Lee A, Zheng W, Berasi SP, Huard C, Morrell NW, Chung RT, Channick RW, Roberts KE, Yu PB.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):891-902. doi: 10.1164/rccm.201807-1236OC.

PMID:
30312106
38.

Association Between Aspirin Use and Risk of Hepatocellular Carcinoma.

Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT.

JAMA Oncol. 2018 Dec 1;4(12):1683-1690. doi: 10.1001/jamaoncol.2018.4154.

39.

Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease.

Bhan I, Mosesso K, Goyal L, Philipp J, Kalinich M, Franses JW, Choz M, Oklu R, Toner M, Maheswaran S, Haber DA, Zhu AX, Chung RT, Aryee M, Ting DT.

Gastroenterology. 2018 Dec;155(6):2016-2018.e11. doi: 10.1053/j.gastro.2018.09.020. Epub 2018 Sep 13. No abstract available.

PMID:
30218669
40.

Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity.

Luther J, Gala MK, Borren N, Masia R, Goodman RP, Moeller IH, DiGiacomo E, Ehrlich A, Warren A, Yarmush ML, Ananthakrishnan A, Corey K, Kaplan LM, Bhatia S, Chung RT, Patel SJ.

Hepatol Commun. 2018 Jul 16;2(7):786-797. doi: 10.1002/hep4.1179. eCollection 2018 Jul.

41.

A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.

Liu X, Duan X, Holmes JA, Li W, Lee SH, Tu Z, Zhu C, Salloum S, Lidofsky A, Schaefer EA, Cai D, Li S, Wang H, Huang Y, Zhao Y, Yu ML, Xu Z, Chen L, Hong J, Lin W, Chung RT.

Hepatology. 2019 Mar;69(3):1004-1019. doi: 10.1002/hep.30266. Epub 2019 Feb 13.

PMID:
30199576
42.

Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring.

Long MT, Gurary EB, Massaro JM, Ma J, Hoffmann U, Chung RT, Benjamin EJ, Loomba R.

Liver Int. 2019 Apr;39(4):740-747. doi: 10.1111/liv.13956. Epub 2018 Sep 25.

PMID:
30179294
43.

Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.

Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT.

Hepatology. 2019 Feb;69(2):729-741. doi: 10.1002/hep.30230. Epub 2019 Jan 4.

PMID:
30141205
44.

Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy.

Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):739-747.e8. doi: 10.1016/j.cgh.2018.08.042. Epub 2018 Aug 21.

PMID:
30138735
45.

Heat Stroke as a Cause of Liver Failure and Evaluation of Liver Transplant.

Martins PN, Brüggenwirth IMA, McDaid J, Hertl M, Kawai T, Elias N, Chung RT, Markmann JF.

Exp Clin Transplant. 2018 Aug 17. doi: 10.6002/ect.2018.0003. [Epub ahead of print]

46.

Opioid Use Disorder, Stigma, and Transplantation: A Call to Action.

Wakeman SE, Ladin K, Brennan T, Chung RT.

Ann Intern Med. 2018 Aug 7;169(3):188-189. doi: 10.7326/M18-1099. Epub 2018 Jul 10. No abstract available.

PMID:
29987319
47.

The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.

Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP.

Int J Cardiol. 2018 Nov 1;270:245-252. doi: 10.1016/j.ijcard.2018.05.087. Epub 2018 May 26.

48.

Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.

Lidofsky A, Holmes JA, Feeney ER, Kruger AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE, Gustafson JL, Schaefer EA, Hunt PW, Deeks S, Somsouk M, Chew KW, Chung RT, Alatrakchi N.

J Infect Dis. 2018 Sep 22;218(9):1394-1403. doi: 10.1093/infdis/jiy331.

49.

Patients With Cirrhosis Require More Fecal Microbiota Capsules to Cure Refractory and Recurrent Clostridium difficile Infections.

Pringle PL, Soto MT, Chung RT, Hohmann E.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):791-793. doi: 10.1016/j.cgh.2018.05.038. Epub 2018 May 31.

PMID:
29859984
50.

IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease.

Simon TG, Van Der Sloot KWJ, Chin SB, Joshi AD, Lochhead P, Ananthakrishnan AN, Xavier R, Chung RT, Khalili H.

Inflamm Bowel Dis. 2018 Sep 15;24(10):2247-2257. doi: 10.1093/ibd/izy128.

Supplemental Content

Loading ...
Support Center